Long-term follow-up for alcoholic liver cirrhosis treatment
Part of Digestive system clinical trials.
This study checks on patients with alcoholic liver cirrhosis who previously received an experimental treatment called Cellgram-LC. It aims to track their health over time to learn more about the treatment's long-term effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken part in the earlier Cellgram-LC study (PMC-P-07).
- You need to agree to join this follow-up study by signing a consent form.
- There are no other restrictions for joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether a cell medicine called Cellgram-LC, delivered through a catheter into the liver artery, is safer and works better for people with alcoholic cirrhosis. It may help improve outcomes in people with more advanced liver scarring.
This trial is a follow-up study for people who received the experimental cell therapy (Cellgram-ED) in a previous trial for erectile dysfunction after prostate removal. It checks on your long-term safety and how you are doing.
This study tests remote monitoring for people with liver cirrhosis. Instead of always coming to the clinic, you may use tools at home to track your health, which could make managing your condition easier.
This study tests an injection called CUD005 for people with advanced liver cirrhosis that is causing complications. The goal is to see if it is safe and can help improve liver function.
This study compares patterns of liver inflammation and the liver’s healing ability in people with alcohol-related liver disease, using blood tests and (in most cases) a liver tissue sample. It may help doctors better understand what is happening in the liver and how it may recover.
This study is a long-term follow-up for people who have already received the investigational drug CLBR001. It aims to monitor their health over time after the treatment.
Hear when a new Alcoholic Liver Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.